You’ve tried antidepressant after antidepressant. Maybe you’ve counted pills in weekly organizers for years, adjusted doses, switched medications, combined therapies. Yet here you are, still struggling with symptoms that won’t budge. If this sounds familiar, you’re not alone. About one in three people with depression don’t find relief with traditional treatments. But on March 5, 2019, something changed. The FDA approved Spravato (esketamine nasal spray), marking the first genuinely new approach to treating depression in over three decades. At Resilience Integrative Wellness, we’ve witnessed how this breakthrough treatment offers hope where conventional medications have fallen short.
This isn’t just another antidepressant entering an already crowded market. Spravato’s approval represented a fundamental shift in how we understand and treat depression, especially for those facing treatment resistant conditions.
Why Spravato’s FDA Approval Was Different
Most antidepressants work through similar mechanisms, targeting serotonin, norepinephrine, or dopamine pathways. They’re variations on the same theme. Spravato broke that pattern entirely. Instead of following the well worn path of previous medications, it acts on the brain’s glutamate system through NMDA receptors, offering a completely different route to relief.
The FDA doesn’t hand out approvals lightly, especially for psychiatric medications. The agency granted Spravato both Breakthrough Therapy and Fast Track designations, recognition reserved for treatments addressing serious conditions where existing options fall short. This expedited development and review process reflected the urgent need for new treatment approaches in mental health care.
What made the approval truly groundbreaking was its specific indication. Spravato wasn’t approved for general depression. It received approval for treatment resistant depression in adults, a population that had been largely underserved by existing medications. The FDA defined this as depression that hadn’t responded adequately to at least two different antidepressant treatments. For the first time, people who’d exhausted their options had an FDA approved alternative backed by rigorous clinical research.
The Clinical Trials That Made History
The path to FDA approval involved extensive research across multiple clinical trials. The pivotal studies enrolled patients who’d tried multiple antidepressants without success, people who’d nearly given up hope of finding relief. These weren’t easy cases. These were individuals who represented the real world challenge of treatment resistant depression.
In the TRANSFORM clinical trials, researchers compared Spravato plus an oral antidepressant against placebo plus an oral antidepressant. The results were striking. Patients receiving Spravato showed significantly greater improvements in depression symptoms, often within 24 hours of their first treatment. Traditional antidepressants typically take four to eight weeks to show benefits, if they work at all.
The SUSTAIN study examined whether these benefits lasted over time. Patients who responded to Spravato during an initial treatment phase were randomized to either continue treatment or switch to placebo. Those who stayed on Spravato were 51% less likely to experience relapse compared to those who switched to placebo. This demonstrated that Spravato didn’t just provide temporary relief but could help maintain stability over the long term.
Perhaps most importantly, the ASPIRE studies investigated Spravato’s effects on people experiencing suicidal thoughts alongside depression. The results showed rapid reduction in suicidal ideation, addressing one of the most urgent and dangerous aspects of severe depression. This led to an expanded FDA approval in 2020 for depressive disorder with acute suicidal ideation or behavior.
How the REMS Program Ensures Safety
With Spravato’s unique mechanism and effects came unique safety considerations. The FDA didn’t simply approve the medication and send it out to pharmacies. Instead, they implemented a Risk Evaluation and Mitigation Strategy, or REMS program, to ensure safe administration.
Here’s what that means for patients. You can’t pick up Spravato at your local pharmacy and take it home. The medication must be administered in a certified healthcare setting by trained providers. After each treatment session, you’ll remain under observation for at least two hours to monitor for potential side effects like sedation, dissociation, or temporary increases in blood pressure.
At Resilience Integrative Wellness, our team is fully certified through the REMS program. We’ve completed specialized training in administering Spravato and monitoring patients during and after treatment. Our private treatment rooms provide a comfortable, calming environment where you can relax during the observation period.
The REMS requirements might seem restrictive, but they serve an important purpose. They ensure that every patient receives Spravato in the safest possible setting with appropriate medical oversight. This structured approach has helped maintain an excellent safety profile as real world use has expanded since approval.
What Spravato Approval Meant for Treatment Resistant Depression
Before Spravato’s approval, treatment options for people who didn’t respond to standard antidepressants were limited. You might try combining medications, adding adjunctive treatments, or exploring therapies like transcranial magnetic stimulation. These approaches help some people, but they don’t work for everyone.
Spravato’s approval validated what researchers had been exploring for years through off label ketamine use. It confirmed that targeting the glutamate system could provide rapid, significant relief for depression. More than that, it gave treatment resistant depression the attention and resources it deserved. The condition affects millions of Americans, yet it had long been treated as simply “difficult depression” rather than a distinct clinical challenge requiring specialized approaches.
The approval also sparked broader conversations about innovation in psychiatry. For decades, depression treatment had relied on variations of the same drug classes developed in the 1950s and 1980s. Spravato demonstrated that truly novel mechanisms could be developed, tested, and brought to patients. It opened doors for other innovative treatments and renewed research interest in rapid acting antidepressants.
Insurance coverage followed FDA approval. While ketamine infusions for depression typically aren’t covered by insurance due to their off label status, many insurance plans now cover Spravato for approved indications. This makes cutting edge treatment accessible to people who might not otherwise afford it.
The Science Behind Spravato’s Effectiveness
Understanding how Spravato works helps explain why it succeeds where other treatments fail. Traditional antidepressants increase levels of serotonin, norepinephrine, or dopamine by preventing their reuptake or breakdown. They’re working with neurotransmitter systems that may already be functioning as well as possible in treatment resistant cases.
Spravato takes a different approach. It’s an NMDA receptor antagonist, meaning it blocks these receptors in the brain. This blocking action triggers a cascade of effects. It increases glutamate release, which activates another type of receptor called AMPA receptors. This activation promotes the production of brain derived neurotrophic factor, or BDNF, a protein that helps neurons grow and form new connections.
Think of it as neuroplasticity in action. Depression often involves rigid, dysfunctional patterns of neural activity. Spravato helps break these patterns by promoting the formation of new neural pathways. It’s not just masking symptoms but potentially helping the brain rewire itself toward healthier patterns of function.
The rapid onset of effects sets Spravato apart from conventional treatments. While oral antidepressants need weeks to alter neurotransmitter levels gradually, Spravato’s mechanism produces changes within hours. For someone in crisis, particularly someone experiencing suicidal thoughts, this speed can be life saving.
Spravato’s Journey from Approval to Real World Use
Following the FDA’s 2019 approval announcement, Spravato became available to patients that same month. The rollout involved certifying healthcare facilities and providers through the REMS program. Clinics like ours worked to establish treatment protocols, train staff, and create appropriate spaces for administration and observation.
Real world experience has largely confirmed what clinical trials suggested. Patients who hadn’t responded to multiple antidepressants often find relief with Spravato. The treatment’s effectiveness extends beyond numbers on depression rating scales. People report feeling more like themselves, reconnecting with family and friends, returning to activities they’d abandoned. These qualitative improvements matter just as much as the quantitative measures used in research.
Healthcare providers have learned how to optimize treatment protocols through experience. Initial dosing typically involves twice weekly sessions for the first four weeks, followed by weekly or less frequent maintenance sessions. However, the specific schedule may be adjusted based on individual response. Some patients achieve stable remission and eventually discontinue treatment, while others benefit from ongoing maintenance sessions.
Side effects in practice have been manageable and temporary. Dissociation, described as feeling detached or dreamlike, typically resolves within 90 minutes. Some patients experience mild nausea, dizziness, or temporary changes in perception. These effects occur during and shortly after treatment but don’t persist. Most people can return to normal activities by the next day, though we recommend arranging transportation home after each session.
Comparing Spravato to Ketamine Infusions
You might wonder how Spravato relates to ketamine infusions, which had been used off label for depression for years before Spravato’s approval. Both treatments work through similar mechanisms, but there are important differences.
Spravato contains only esketamine, the S enantiomer of ketamine. Standard ketamine is a racemic mixture containing both S ketamine and R ketamine. Research suggests the S form may be more potent at producing antidepressant effects with fewer side effects. However, some researchers believe the R form contributes meaningful benefits, so this remains an area of ongoing investigation.
Administration differs significantly. Ketamine for depression is given as an intravenous infusion lasting 40 to 60 minutes. Spravato is a nasal spray you self administer under medical supervision. Many patients find the nasal spray less invasive and more comfortable than IV infusions.
The most practical difference is insurance coverage. Spravato treatment in San Diego is often covered by insurance for approved indications, while ketamine infusions typically require out of pocket payment. This makes Spravato more accessible for many people.
Both treatments require administration in a clinical setting with post treatment observation. Both can provide rapid relief for treatment resistant depression. The choice between them often comes down to insurance coverage, individual response, and patient preference. Our team can help you understand which option might work best for your situation.
What to Expect When Starting Spravato Treatment
Beginning Spravato treatment involves several steps. First, we’ll conduct a comprehensive evaluation to confirm you meet criteria for treatment resistant depression. This means documenting that you’ve tried at least two different antidepressants at adequate doses for sufficient duration without achieving remission. We’ll also review your medical history to ensure Spravato is safe for you.
If Spravato is appropriate, we’ll work with your insurance to obtain authorization. The approval process typically takes one to two weeks, though timelines vary by insurance provider. Once approved, we’ll schedule your first treatment session.
On treatment days, you’ll arrive at our clinic having avoided food for at least two hours and drinks for at least 30 minutes before your session. This reduces the risk of nausea. We’ll check your blood pressure before treatment, as Spravato can cause temporary increases.
You’ll self administer the nasal spray under our supervision in a private, comfortable treatment room. The process is straightforward. The spray device contains pre measured doses, and we’ll guide you through proper administration technique. Most people find it easy and comfortable.
After administration, you’ll relax in the treatment room for at least two hours. You might read, listen to music, rest, or simply be with your thoughts. Some people experience dissociation or changes in perception during this time. These effects are temporary and typically resolve before you leave. We’ll check on you regularly and monitor your blood pressure.
Before you go home, we’ll ensure you’re stable and symptom free. You’ll need someone to drive you, as you shouldn’t drive or operate machinery for the rest of the day. Most people feel back to normal by the next morning.
The Future of Depression Treatment After Spravato
Spravato’s approval didn’t just provide a new treatment option. It validated an entirely different approach to developing psychiatric medications. The success has encouraged pharmaceutical companies and researchers to explore other rapid acting treatments targeting the glutamate system and other novel mechanisms.
Research continues on optimizing Spravato use. Studies are examining long term outcomes, identifying which patients respond best, and determining optimal maintenance schedules. Scientists are investigating whether Spravato might benefit other conditions like PTSD, OCD, or anxiety disorders. Early research shows promise, though these remain off label uses pending additional studies and FDA review.
The broader impact extends to how we think about mental health treatment. Spravato demonstrated that depression treatment doesn’t have to follow the slow, gradual approach of traditional antidepressants. Rapid relief is possible. This has implications for suicide prevention, acute crisis intervention, and helping people who need to see improvement quickly to maintain hope.
Other glutamate modulating drugs are now in development, inspired by Spravato’s success. New formulations, delivery methods, and related compounds are being tested. The field of rapid acting antidepressants has expanded dramatically in the years since Spravato’s approval.
Take the Next Step Toward Relief
If you’ve tried multiple antidepressants without finding relief, Spravato might offer the breakthrough you’ve been seeking. Its FDA approval status means it’s backed by rigorous clinical research and often covered by insurance. The rapid onset of effects can provide hope when you need it most.
At Resilience Integrative Wellness, we’re committed to bringing the most advanced, evidence based treatments to our San Diego community. Our veteran owned practice combines innovative approaches like Spravato with compassionate, personalized care. We understand the frustration of treatment resistant depression, and we’re here to help you find a path forward.
Don’t let treatment resistant depression define your future. Contact us today to schedule a consultation and learn whether Spravato might be right for you. You can reach us at (619) 768-8723 or visit our clinic at 6719 Alvarado Road, Suite 201, San Diego, CA 92120. Your journey toward relief can start with a simple phone call.
The information on this page is for educational purposes only and does not constitute medical advice. Individual results may vary. Always consult with a qualified healthcare provider before beginning any new treatment.
